{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T05:38:33Z","timestamp":1706765913647},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2002,3,1]],"date-time":"2002-03-01T00:00:00Z","timestamp":1014940800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2002,3]]},"DOI":"10.1007\/bf03165140","type":"journal-article","created":{"date-parts":[[2009,9,30]],"date-time":"2009-09-30T07:15:00Z","timestamp":1254294900000},"page":"311-317","source":"Crossref","is-referenced-by-count":5,"title":["What is the standard treatment in essential thrombocythemia"],"prefix":"10.1007","volume":"76","author":[{"given":"Tiziano","family":"Barbui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF03165140_CR1","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1182\/blood.V58.5.916.916","volume":"58","author":"PJ Fialkow","year":"1981","unstructured":"Fialkow PJ, Faguet GB, Jacobson RJ, et al. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent cell.Blood. 1981;58:916\u2013919.","journal-title":"Blood."},{"key":"BF03165140_CR2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1182\/blood.V93.2.417","volume":"93","author":"CN Harrison","year":"1999","unstructured":"Harrison CN, Gale RE, Machin SJ, Linch DC. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorders and may be at lower risk of thrombotic complications.Blood. 1999;93:417\u2013424.","journal-title":"Blood."},{"key":"BF03165140_CR3","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1055\/s-0038-1657600","volume":"78","author":"S Murphy","year":"1997","unstructured":"Murphy S. Therapeutic dilemmas: balancing the risk of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD).Thromb Haemostas. 1997;78:622\u2013626.","journal-title":"Thromb Haemostas."},{"key":"BF03165140_CR4","first-page":"597","volume-title":"Thrombosis and Hemorrhage","author":"S Murphy","year":"1994","unstructured":"Murphy S, Iland HJ. Thrombocytosis. In: Thrombosis and Hemorrhage (1st ed.) Loscalzo J and Schafer AL eds. Williams and Wilkins, Baltimore, 1994. pp. 597\u2013612.","edition":"1st ed."},{"key":"BF03165140_CR5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2141.1991.tb04408.x","volume":"78","author":"TC Pearson","year":"1991","unstructured":"Pearson TC. Primary Thrombocythaemia: diagnosis and management.Br J Haematol. 1991;78:145\u2013148.","journal-title":"Br J Haematol."},{"key":"BF03165140_CR6","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1002\/1097-0142(19910515)67:10<2658::AID-CNCR2820671042>3.0.CO;2-C","volume":"67","author":"C Rozman","year":"1991","unstructured":"Rozman C, Giralt M, Feliu E, et al. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders.Cancer. 1991;67:2658\u20132663.","journal-title":"Cancer."},{"key":"BF03165140_CR7","first-page":"177","volume":"23","author":"S Murphy","year":"1986","unstructured":"Murphy S, Iland HJ, Rosenthal D, et al. Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group.Semin Hematol. 1986;23:177\u2013182.","journal-title":"Semin Hematol."},{"key":"BF03165140_CR8","first-page":"29","volume":"34","author":"S Murphy","year":"1997","unstructured":"Murphy S, Peterson P, Iland H, et al. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment.Semin Hematol. 1997;34:29\u201339.","journal-title":"Semin Hematol."},{"key":"BF03165140_CR9","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2141.1989.tb04288.x","volume":"71","author":"JM Dudley","year":"1989","unstructured":"Dudley JM, Messinezy M, Eridani S, et al. Primary thrombocythemia: diagnostic criteria and a simple scoring system for positive diagnosis.Br J Haematol. 1989;71:331\u2013335.","journal-title":"Br J Haematol."},{"key":"BF03165140_CR10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3109\/10428199609074359","volume":"22","author":"J Kutti","year":"1996","unstructured":"Kutti J, Wadenvik H. Diagnostic and differential criteria of essential thrombocyhemia and reactive thrombocytosis.Leuk Lymphoma. 1996;22:41\u201345.","journal-title":"Leuk Lymphoma."},{"key":"BF03165140_CR11","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1600-0609.1994.tb01873.x","volume":"53","author":"BM Sawyer","year":"1994","unstructured":"Sawyer BM, Westwood NB, Pearson TC. Circulating megakaryocyte progenitor cells in patients with primary thrombocythemia and reactive thrombocytosis: results using a serum-deprived culture assay and positive detection technique.Eur J Hematol. 1994;53:108\u2013113.","journal-title":"Eur J Hematol."},{"key":"BF03165140_CR12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1046\/j.1365-2141.1998.00529.x","volume":"100","author":"E Lengfelder","year":"1998","unstructured":"Lengfelder E, Hochhaus A, Kronawitter U, et al. Should a platelet limit of 600\u00d7109\/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages.Br J Haematol. 1998;100:15\u201323,","journal-title":"Br J Haematol."},{"key":"BF03165140_CR13","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/1040-8428(94)00164-O","volume":"20","author":"R Landolfi","year":"1995","unstructured":"Landolfi R, Rocca B, Patrono C. Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment.Crit Review Oncol Hematol. 1995;20:203\u2013222.","journal-title":"Crit Review Oncol Hematol."},{"key":"BF03165140_CR14","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1055\/s-2007-996110","volume":"23","author":"PJ Koudstaal","year":"1997","unstructured":"Koudstaal PJ, Koudstaal A. Neurologic and visual symptoms in essential thrombocythemia: efficacy of low-dose aspirin.Semin Thromb Haemostas. 1997;23:365\u2013370.","journal-title":"Semin Thromb Haemostas."},{"key":"BF03165140_CR15","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1055\/s-2007-996109","volume":"23","author":"PJJ Genderen Van","year":"1997","unstructured":"Van Genderen PJJ, Michiels JJ. Erythromelalgia: a patognomonic microvascular thrombotic complication in essential thrombocythemia and polycythemia vera.Semin Thromb Haemostas. 1997;23:357\u2013364.","journal-title":"Semin Thromb Haemostas."},{"key":"BF03165140_CR16","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1055\/s-2007-996117","volume":"23","author":"V Stefano De","year":"1997","unstructured":"De Stefano V, Teofili L, Leone G, et al. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis.Semin Thromb Haemostas. 1997; 23:411\u2013418.","journal-title":"Semin Thromb Haemostas."},{"key":"BF03165140_CR17","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/0277-5379(83)90091-3","volume":"19","author":"T Barbui","year":"1983","unstructured":"Barbui T, Cortelazzo S, Viero P, et al. Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: Relationship to platelet number and function.Eur J Cancer Clin Oncol. 1983;19:1593\u20131599.","journal-title":"Eur J Cancer Clin Oncol."},{"key":"BF03165140_CR18","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1002\/1097-0142(19861201)58:11<2440::AID-CNCR2820581115>3.0.CO;2-Y","volume":"58","author":"S Bellucci","year":"1986","unstructured":"Bellucci S, Janvier M, Tobelem G, et al. Essential thrombocythemia: Clinical evolutionary and biological data.Cancer. 1986;58:2440\u20132447.","journal-title":"Cancer"},{"key":"BF03165140_CR19","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1002\/1097-0142(19880615)61:12<2487::AID-CNCR2820611217>3.0.CO;2-T","volume":"61","author":"R Hehlmann","year":"1988","unstructured":"Hehlmann R, Jahn M, Baumann B, et al. Essential thrombocythemia: Clinical characteristics and course of 61 cases.Cancer. 1988;61:2487\u20132496.","journal-title":"Cancer."},{"key":"BF03165140_CR20","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/1097-0142(19900801)66:3<549::AID-CNCR2820660324>3.0.CO;2-6","volume":"66","author":"P Fenaux","year":"1990","unstructured":"Fenaux P, Simon M, Caulier MT, et al. Clinical course of essential thrombocythemia in 147 cases.Cancer. 1990;66:549\u2013556.","journal-title":"Cancer."},{"key":"BF03165140_CR21","doi-asserted-by":"crossref","first-page":"29269","DOI":"10.1002\/1097-0142(19910601)67:11<2926::AID-CNCR2820671136>3.0.CO;2-3","volume":"67","author":"M Colombi","year":"1991","unstructured":"Colombi M, Radaelli F, Zocchi L, et al. Thrombotic and hemorrhagic complications in essential thrombocytemia.Cancer. 1991;67:29269\u20132930.","journal-title":"Cancer."},{"issue":"suppl 1","key":"BF03165140_CR22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/10428199609074363","volume":"22","author":"G Finazzi","year":"1996","unstructured":"Finazzi G, Budde U, Michiels JJ. Bleeding time and platelet function in essential thrombocythemia and other myeloproliferative syndromes.Leuk Lymphoma. 1996;22(suppl 1):71\u201378.","journal-title":"Leuk Lymphoma."},{"key":"BF03165140_CR23","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1182\/blood.V91.4.1288","volume":"91","author":"HM Rinder","year":"1998","unstructured":"Rinder HM, Schuster JE, Rinder CS, et al. Correlation of thrombosis with increased platelet turnover in thrombocytosis.Blood. 1998;91:1288\u20131293.","journal-title":"Blood."},{"key":"BF03165140_CR24","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1182\/blood.V82.6.1749.1749","volume":"82","author":"U Budde","year":"1993","unstructured":"Budde U, Scharf RE, Franke P, et al. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma.Blood. 1993;82:1749\u20131757.","journal-title":"Blood."},{"key":"BF03165140_CR25","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/BF01698487","volume":"69","author":"PJJ Genderen Van","year":"1994","unstructured":"Van Genderen PJJ, Michiels JJ, van der Poel-van de Luytgaarde SCPAM, et al. Acquired von Willebrand disease as a cause of recurrent mucocutaneous bleeding in primary thrombocythemia: relationship with platelet count.Ann Hematol. 1994;69:81\u201384.","journal-title":"Ann Hematol."},{"key":"BF03165140_CR26","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.1990.8.3.556","volume":"8","author":"S Cortelazzo","year":"1990","unstructured":"Cortelazzo S, Viero P, Finazzi G, et al. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia.J Clin Oncol. 1990;8:556\u2013562.","journal-title":"J Clin Oncol."},{"key":"BF03165140_CR27","first-page":"402","volume":"77","author":"ML Randi","year":"1992","unstructured":"Randi ML, Fabris F, Rossi C, et al. Sex and age as prognostic factors in essential thrombocythemia.Haematologica. 1992;77:402\u2013404.","journal-title":"Haematologica"},{"key":"BF03165140_CR28","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0025-6196(12)60486-8","volume":"66","author":"K McIntyre","year":"1991","unstructured":"McIntyre K, Hoagland H, Silverstein M, et al. Essential thrombocythemia in young adults.Mayo Clin Proc. 1991;66: 149\u2013154.","journal-title":"Mayo Clin Proc."},{"key":"BF03165140_CR29","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/0002-9343(90)90491-U","volume":"88","author":"AJ Mitus","year":"1990","unstructured":"Mitus AJ, Barbui T, Shulman LN, et al. Hemostatic complications in young patients with essential thrombocythemia.Am J Med. 1990;88:371\u2013375.","journal-title":"Am J Med."},{"key":"BF03165140_CR30","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1600-0609.1990.tb00355.x","volume":"44","author":"J Kutti","year":"1990","unstructured":"Kutti J. The management of thrombocytosis.Eur J Haematol. 1990;44:81\u201388.","journal-title":"Eur J Haematol."},{"key":"BF03165140_CR31","first-page":"69","volume":"10","author":"AI Schafer","year":"1991","unstructured":"Schafer AI. Essential thrombocythemia.Progr Hemostas Thromb. 1991;10:69\u201396.","journal-title":"Progr Hemostas Thromb."},{"key":"BF03165140_CR32","first-page":"334","volume":"22","author":"A Tefferi","year":"1995","unstructured":"Tefferi A, Silverstein MN, Hoagland HC. Primary thrombocythemia.Semin Oncol. 1995;22:334\u2013340.","journal-title":"Semin Oncol."},{"issue":"suppl 1","key":"BF03165140_CR33","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3109\/10428199609074373","volume":"22","author":"T Barbui","year":"1996","unstructured":"Barbui T, Finazzi G, Dupuy E, et al. Treatment strategies in essential thrombocythemia.Leuk Lymphoma. 1996;22(suppl 1): 149\u2013160.","journal-title":"Leuk Lymphoma."},{"key":"BF03165140_CR34","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1055\/s-2007-996111","volume":"23","author":"M Griesshammer","year":"1997","unstructured":"Griesshammer M, Bangerter M, vanVliet HHDM, et al. Aspirin in essential thrombocythemia: status quo and quo vadis.Semin Thromb Haemostas. 1997;23:371\u2013378.","journal-title":"Semin Thromb Haemostas."},{"key":"BF03165140_CR35","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","volume":"308","author":"Antiplatelet Trialists\u2019 Collaboration","year":"1994","unstructured":"Antiplatelet Trialists\u2019 Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients.Br Med J. 1994;308: 81\u2013106.","journal-title":"Br Med J."},{"key":"BF03165140_CR36","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(96)01254-8","volume":"348","author":"JP Kelly","year":"1996","unstructured":"Kelly JP, Kaufman DW, Jurgelon JM, et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product.Lancet. 1996;348:1413\u20131416.","journal-title":"Lancet."},{"key":"BF03165140_CR37","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/(SICI)1096-8652(199609)53:1<6::AID-AJH2>3.0.CO;2-V","volume":"53","author":"P Pagliaro","year":"1996","unstructured":"Pagliaro P, Arrigoni L, Muggiasca ML, et al. Primary thrombocyhthemia and pregnancy. Treatment and outcome in fifteen cases.Am J Hematol. 1996;53:6\u201310.","journal-title":"Am J Hematol."},{"issue":"suppl 1","key":"BF03165140_CR38","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3109\/10428199609074361","volume":"22","author":"M Griesshammer","year":"1996","unstructured":"Griesshammer M, Heimpel H, Pearson TC. Essential thrombocythaemia and pregnancy.Leuk Lymphoma. 1996;22(suppl 1): 57\u201363.","journal-title":"Leuk Lymphoma."},{"key":"BF03165140_CR39","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/archinte.1995.00430110137015","volume":"155","author":"AH Beressi","year":"1995","unstructured":"Beressi AH, Tefferi A, Silverstein MN, et al. Outcome analysis of 34 pregnancies in women with essential thrombocythemia.Arch Intern Med. 1995;155:1217\u20131222.","journal-title":"Arch Intern Med."},{"key":"BF03165140_CR40","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1046\/j.1365-2141.1996.d01-1476.x","volume":"92","author":"O Shpilberg","year":"1996","unstructured":"Shpilberg O, Shimon I, Sofer O, et al. Transient normal platelet count and decreased requirement for interferon during pregnancy in essential thrombocythemia.Br J Haematol. 1996;92:491\u2013493.","journal-title":"Br J Haematol."},{"key":"BF03165140_CR41","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1600-0609.1988.tb00212.x","volume":"41","author":"E Lofvenberg","year":"1988","unstructured":"Lofvenberg E, Walhlin A. Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea.Eur J Haematol. 1988;41:375\u2013381.","journal-title":"Eur J Haematol."},{"key":"BF03165140_CR42","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","volume":"332","author":"S Cortelazzo","year":"1995","unstructured":"Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea in the treatment of patients with essential thrombocythemia at high risk of thrombosis: a prospective randomized trial.N Engl J Med. 1995;332:1132\u20131136.","journal-title":"N Engl J Med."},{"key":"BF03165140_CR43","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0190-9622(97)70276-7","volume":"36","author":"MS Daoud","year":"1997","unstructured":"Daoud MS, Gibson LE, Pittelkow MR. Hydroxyurea dermopathy: a unique lichenoid eruption complicating long-term therapy with hydroxyurea.J Am Acad Dermatol. 1997;36:178\u2013182.","journal-title":"J Am Acad Dermatol."},{"key":"BF03165140_CR44","doi-asserted-by":"crossref","first-page":"29","DOI":"10.7326\/0003-4819-128-1-199801010-00005","volume":"128","author":"P Best","year":"1998","unstructured":"Best P, Daoud MS, Pittelkow MR et al. Hydroxyurea-induced leg ulceration in 14 patients.Ann Intern Med. 1998;128:29\u201332.","journal-title":"Ann Intern Med."},{"key":"BF03165140_CR45","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/(SICI)1096-8652(199605)52:1<42::AID-AJH7>3.0.CO;2-6","volume":"52","author":"S Nand","year":"1996","unstructured":"Nand S, Stock W, Godwin J, et al. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis.Am J Hematol. 1996;52:42\u201346.","journal-title":"Am J Hematol."},{"key":"BF03165140_CR46","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0165-4608(90)90164-6","volume":"49","author":"E Lfvenberg","year":"1990","unstructured":"Lfvenberg E, Nordenson I, Walhlin A. Cytogenetic abnormalities and leukemic transformation in hydroxyurea-treated patients with Philadelphia chromosome negative chronic myeloproliferative disease.Cancer Genet Cytogenet. 1990;49:57\u201367.","journal-title":"Cancer Genet Cytogenet."},{"key":"BF03165140_CR47","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1600-0609.1994.tb01303.x","volume":"52","author":"A Weinfield","year":"1994","unstructured":"Weinfield A, Swolin B, Westin J. Acute leukaemia after hydroxyurea therapy in polycythemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications.Eur J Haematol. 1994;52:134\u2013139.","journal-title":"Eur J Haematol."},{"key":"BF03165140_CR48","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V91.2.616","volume":"91","author":"Y Sterkers","year":"1988","unstructured":"Sterkers Y, Preudhomme C, Lai J-L, et al. Acute myeloid leukemia and myelodyslastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion.Blood. 1988;91:616\u2013622.","journal-title":"Blood."},{"key":"BF03165140_CR49","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000204260","volume":"91","author":"K Shibata","year":"1994","unstructured":"Shibata K, Shimamoto Y, Suga K, et al. Essential Thrombocythemia terminating in acute leukemia with minimal myeloid differentiation. A brief review of recent literature.Acta Haematol. 1994;91:84\u201388.","journal-title":"Acta Haematol."},{"key":"BF03165140_CR50","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1046\/j.1365-2141.2000.02188.x","volume":"110","author":"G Finazzi","year":"2000","unstructured":"Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocythaemia treated with busulfan and hydroxyurea: long-term follow-up of a randomized clinical trial.Br J Haematol. 2000;110:577\u2013583.","journal-title":"Br J Haematol."},{"key":"BF03165140_CR51","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1365-2141.1986.tb02926.x","volume":"62","author":"JEW Pette Van de","year":"1986","unstructured":"Van de Pette JEW, Prochazka AV, Pearson TC, et al. Primary thrombocythemia treated with busulfan.Br J Haematol. 1986; 62:229\u2013237.","journal-title":"Br J Haematol."},{"key":"BF03165140_CR52","first-page":"132","volume":"23","author":"P Berk","year":"1986","unstructured":"Berk P, Goldberg J, Donovan P, et al. Therapeutic recommendations in polycythemia vera based on polycythemia vera study group protocols.Semin Hematol. 1986;23:132\u2013143.","journal-title":"Semin Hematol."},{"key":"BF03165140_CR53","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/bjc.1981.150","volume":"44","author":"C Haanen","year":"1981","unstructured":"Haanen C, Mathe G for the EORTC. Treatment of polycythaemia vera by radioactive phosphorus or busulphan.Br J Cancer. 1981;44:75\u201378.","journal-title":"Br J Cancer."},{"issue":"suppl 1","key":"BF03165140_CR54","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3109\/10428199609074371","volume":"22","author":"E Lengfelder","year":"1996","unstructured":"Lengfelder E, Griesshammer M, Hehlmann R. Interferon-alpha in the treatment of essential thrombocythemia.Leuk Lymphoma. 1996;22(suppl 1):135\u2013142.","journal-title":"Leuk Lymphoma"},{"key":"BF03165140_CR55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0268-960X(97)90001-1","volume":"11","author":"A Tefferi","year":"1997","unstructured":"Tefferi A, Elliot MA, Solberg LA Jr, et al. New drugs in essential thrombocythemia and polycythemia vera.Blood Reviews. 1997;11:1\u20137.","journal-title":"Blood Reviews"},{"key":"BF03165140_CR56","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1055\/s-2007-996112","volume":"23","author":"A Tefferi","year":"1997","unstructured":"Tefferi A, Silverstein MN, Petitt RM, et al. Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of action, efficacy, toxicity, current indication.Semin Thromb Hemostas. 1997;23:379\u2013384.","journal-title":"Semin Thromb Hemostas."},{"key":"BF03165140_CR57","first-page":"51","volume":"34","author":"RM Petitt","year":"1997","unstructured":"Petitt RM, Silverstein MN, Petrone ME. Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders.Semi Hematol. 1997;34:51\u201354.","journal-title":"Semi Hematol."},{"key":"BF03165140_CR58","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0002-9343(92)90017-6","volume":"92","author":"Anagrelide Study Group","year":"1992","unstructured":"Anagrelide Study Group. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients.Am J Med. 1992; 92:69\u201376.","journal-title":"Am J Med."},{"key":"BF03165140_CR59","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V97.4.863","volume":"97","author":"EC Storen","year":"2001","unstructured":"Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia.Blood. 2001;97:863\u2013866.","journal-title":"Blood."}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03165140.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03165140\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03165140","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T16:24:53Z","timestamp":1590164693000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03165140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,3]]},"references-count":59,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2002,3]]}},"alternative-id":["BF03165140"],"URL":"https:\/\/doi.org\/10.1007\/bf03165140","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,3]]}}}